- ISIN
- US57777K1060
- Sector
- Healthcare
- Industry
- Medical Devices
- IPO Date
- Jul 30, 2021
Highlights
- Market Cap
- $112.48M
- Enterprise Value
- $116.78M
- EPS (TTM)
- -$0.37
- Total Revenue (TTM)
- $32.29M
- Gross Profit (TTM)
- $21.77M
- EBITDA (TTM)
- -$34.05M
- Year Range
- $0.64 - $2.19
- Target Price
- $6.00
- ROA (TTM)
- -20.12%
- ROE (TTM)
- -23.30%
- Avg. Volume (1M)
- 995K
- Avg. Volume Value (1M)
- $1.23M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
MXCT Performance Chart
MaxCyte Inc (MXCT) is down 32.3% since the beginning of the year. At $1 per share, MXCT is trading 52.1% below its 52-week high of $2. Investors who bought $1,000 worth of MXCT shares 5 years ago would now be looking at an investment worth $62.
Loading charts...
Compare this symbol against anything
Returns By Period
MaxCyte Inc (MXCT) has returned -32.26% so far this year and -48.53% over the past 12 months.
MaxCyte Inc
- 1D
- 0.00%
- 1M
- -13.58%
- 6M
- 15.79%
- YTD
- -32.26%
- 1Y
- -48.53%
- 3Y*
- -38.44%
- 5Y*
- -42.70%
- 10Y*
- —
- ALL TIME*
- -42.68%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
MXCT Monthly Returns History
Based on dividend-adjusted daily data since Jul 30, 2021, MXCT's average daily return is -0.13%, while the average monthly return is -2.97%.
Historically, 39% of months were positive and 61% were negative. The best month was Nov 2023 with a return of +60.5%, while the worst month was Jan 2026 at -41.5%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 4 months.
On a daily basis, MXCT closed higher 45% of trading days. The best single day was May 13, 2026 with a return of +24.1%, while the worst single day was Aug 7, 2025 at -29.9%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -41.50% | -10.53% | -13.41% | 25.27% | 37.50% | 1.65% | -14.63% | -32.26% | |||||
| 2025 | 8.41% | -25.94% | -18.26% | 4.03% | -16.20% | -8.40% | -5.50% | -32.52% | 13.67% | -2.53% | 14.29% | -11.93% | -62.74% |
| 2024 | 8.30% | -9.63% | -8.91% | -13.37% | 23.42% | -12.50% | 22.45% | -10.00% | -9.95% | -7.97% | -0.84% | 17.18% | -11.49% |
| 2023 | 6.96% | -22.26% | 9.03% | 1.01% | -18.40% | 12.50% | -2.61% | -18.12% | -14.75% | -5.13% | 60.47% | -1.05% | -13.92% |
| 2022 | -36.60% | 7.74% | 0.43% | -20.74% | -16.79% | 2.60% | 15.22% | -4.59% | 25.00% | 6.46% | -13.44% | -8.85% | -46.42% |
| 2021 | 0.06% | -9.65% | -20.51% | -7.94% | -11.21% | 2.10% | -40.02% |
Benchmark Metrics
MaxCyte Inc has an annualized alpha of -39.23%, beta of 1.46, and R2 of 0.13 versus S&P 500 Index. Calculated based on daily prices since July 30, 2021.
- This stock participated in 205.88% of S&P 500 Index downside but only -11.45% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.13 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -39.23%
- Beta
- 1.46
- R²
- 0.13
- Upside Capture
- -11.45%
- Downside Capture
- 205.88%
Return for Risk
Risk / Return Rank
MXCT ranks 16 for risk / return — above 16% of stocks peers on PortfoliosLab. Its historical combined result is below most peers; review the five component ranks for context.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for MaxCyte Inc (MXCT) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| MXCT | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.08 | ||
| Sortino ratioReturn per unit of downside risk | -2.71 | ||
| Omega ratioGain probability vs. loss probability | 0.91 | 1.25 | -0.34 |
| Calmar ratioReturn relative to maximum drawdown | -0.73 | 2.00 | -2.73 |
| Martin ratioReturn relative to average drawdown | -1.13 | 8.49 | -9.62 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the MaxCyte Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the MaxCyte Inc was 96.07%, occurring on Mar 30, 2026. The portfolio has not yet recovered.
The current MaxCyte Inc drawdown is 93.90%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-96.07%Mar 2026 | 4y 6mo | — | 4y 11moSep 2021 - now | — |
-19.65%Aug 2021 | 23d | 9d | 1mo 2dAug 2021 - Sep 2021 | — |
Drawdown Indicators
| MXCT | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.07% | -56.78% | -39.29% |
Max Drawdown (1Y)Largest decline over 1 year | -67.49% | -9.10% | -58.39% |
Max Drawdown (3Y)Largest decline over 3 years | -87.42% | -18.90% | -68.52% |
Max Drawdown (5Y)Largest decline over 5 years | -96.07% | -25.43% | -70.64% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -93.90% | -1.58% | -92.32% |
Average DrawdownAverage peak-to-trough decline | -73.47% | -10.70% | -62.77% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 43.58% | 2.14% | +41.44% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of MaxCyte Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how MaxCyte Inc is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for MXCT relative to other companies in the Medical Devices industry. Currently, MXCT has a P/S ratio of 3.5. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for MXCT in comparison with other companies in the Medical Devices industry. Currently, MXCT has a P/B value of 0.7. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with MXCT
Add MaxCyte Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with MXCT